Stockscreener 앱 받기
304.84
0.74%
-2.26
Insulet Corporation 주식(PODD)의 최신 뉴스
Why Insulet (PODD) is a Top Growth Stock for the Long-Term - sharewise.com
Insulet Corp: Strong Financial Position and Competitive Strengths - AInvest
Price Consolidation Hints at Upcoming Move in Insulet CorporationFast Exit and Entry Strategy Guide Offered - beatles.ru
Insulin pump makers Tandem and Insulet post contrasting Q2 results - MSN
Quant Strategy Flags Insulet Corporation for EntryTrade Scanner With Buy Zone Alerts Flagged - beatles.ru
Insulet's Insider Activity and Executive Compensation Transparency: A Governance and Investor Sentiment Analysis - AInvest
Research Alert: CFRA Maintains Hold Opinion On Shares Of Insulet Corporation - 富途牛牛
RBC Capital Raises PT for Insulet to $350, Maintains Outperform Rating - AInvest
Insulet Corporation shares rise 2.61% intraday after multiple brokerages raised price targets. - AInvest
Insulet (PODD) Is Up 5.3% After Raising Full-Year Revenue Guidance on Strong Q2 Sales – Has The Bull Case Changed? - simplywall.st
Baird Adjusts Price Target on Insulet to $360 From $350, Maintains Outperform Rating - MarketScreener
Insulet stock price target raised to $350 from $330 at RBC Capital - Investing.com Canada
Bernstein raises Insulet stock price target to $400 on type 2 diabetes growth - Investing.com Nigeria
RBC Raises Price Target on Insulet to $350 From $330, Keeps Outperform Rating - MarketScreener
Insulet price target raised to $350 from $330 at RBC Capital - TipRanks
Insulet Corporation (PODD) PT Raised to $350 at RBC Capital - StreetInsider
Insulet Corporation (NASDAQ:PODD) Q2 2025 Earnings Call Transcript - Insider Monkey
Insulet Corporation (PODD) PT Raised to $400 at Bernstein SocGen Group - StreetInsider
Insulet price target raised to $353 from $331 at Canaccord - TipRanks
Morgan Stanley Raises Price Target on Insulet to $370 From $355, Keeps Overweight Rating - MarketScreener
Goldman Sachs Adjusts Price Target on Insulet to $399 From $380, Maintains Buy Rating - MarketScreener
Canaccord Genuity Adjusts Price Target on Insulet to $353 From $331, Maintains Buy Rating - MarketScreener
Bernstein Adjusts Price Target on Insulet to $400 From $375, Maintains Outperform Rating - MarketScreener
Tandem, Insulet monitoring CMS payment proposal for diabetes tech - Yahoo Finance
Insulet raises full-year 2025 revenue growth guidance to 24%-27% as Omnipod 5 drives global adoption - MSN
Insulet Corp (PODD) Q2 2025 Earnings Call Highlights: Record Revenue and Raised Guidance Amid ... By GuruFocus - Investing.com Canada
Insulet Corporation Reports Strong Q2 2025 Growth - TipRanks
Insulet Corp. stock outperforms competitors on strong trading day - MSN
Insulet: Q2 Earnings Snapshot - Stamford Advocate
Insulet Corp. Q2 Profit Decreases, But Beats Estimates - Nasdaq
Insulet’s Earnings Call Highlights Robust Growth and Optimism - TipRanks
Canaccord Genuity raises Insulet stock price target to $353 on strong growth - Investing.com Nigeria
Insulet Corporation (PODD) PT Raised to $353 at Canaccord Genuity - StreetInsider
Insulet Ups The Pace Thanks To Demand For Its Wearable Pump - Finimize
Insulet’s Wearable Pumps Propel Earnings Past Wall Street Goals - Finimize
Leerink Partners Raises Price Target on Insulet to $339 From $333 - MarketScreener
Wells Fargo Adjusts Price Target on Insulet to $350 From $330, Maintains Overweight Rating - MarketScreener
Insulet (NASDAQ:PODD) Beats Expectations in Strong Q2, Stock Soars - Yahoo Finance
Insulet Peer Tandem Diabetes Underwhelming Earnings, Dull Outlook Drags Stock - Benzinga
Jefferies raises Insulet stock price target to $375 on strong Q2 results - Investing.com Nigeria
Insulet Lifts Annual Forecast On Increased Adoption For Insulin Pump Omnipod 5 - inkl
Jefferies Adjusts Insulet Price Target to $375 From $360, Maintains Buy Rating - MarketScreener
Insulet Corporation (PODD) PT Raised to $375 at Jefferies - StreetInsider
Insulet Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: Insulet beats Q2 2025 forecasts, stock surges - Investing.com
Insulet Puts More Competitive Pressure on Tandem - Morningstar
Transcript : Insulet Corporation, Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Insulet's Q2 2025: Navigating Contradictions in U.S. Growth, Type 2 Diabetes Expectations, and Global Strategy - AInvest
Insulet (PODD) Q2 2025 Earnings: Sustained Growth, Margin Expansion, and Strategic Momentum - AInvest
Tandem stock down, Insulet stock up on Q2 prints (PODD:NASDAQ) - Seeking Alpha
Insulet 2025 Q2 Earnings Revenue Surges 32.9%, but Net Income Plummets 88.1% - AInvest
Insulet (PODD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
0.51%
1.39%
자본화:
|
볼륨(24시간):